Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetic Comparisons of Two Donepezil Formulations

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Males age 20 to 45 years~* Body weight \> 45 kg with +/- 20% of ideal body weight~* Signed and dated informed consent form which meets all criteria of current FDA and KFDA regulations~Exclusion Criteria:~* subjects with acute conditions.~* presence of history affecting ADME~* Clinically significant history or current evidence of a hepatic, renal, gastrointestinal, or hematologic abnormality~* Hepatitis B, hepatitis C, or HIV infection revealed on the laboratory findings~* Any other acute or chronic disease~* A history of hypersensitivity to donepezil~* A history of alcohol or drug abuse~* Participation in another clinical trial within 3 months~* smoked \>10 cigarettes daily~* consumption over 5 glasses daily of beverages containing xanthine derivatives~* use of any medication having the potential to affect the study results within 10 days before the start of the study.

- Gender: MALE
- Minimum Age: 20 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Reference arm (Type: ACTIVE_COMPARATOR): Treated with Reference (Aricept, 10 mg donepezil tablet)
- Test arm (Type: EXPERIMENTAL): Treated with Test (Neuropezil, 10 donepezil ODT, orally disintegrating tablet)

Based on this trial design, predict the completion outcome and termination type (if applicable).